Bio Medica Laboratories IPO Description – Incorporated in 2015, Bio Medica Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations, specifically liquid injectables and dry powder injectables, catering to both human and veterinary applications. The product portfolio comprises 58 liquid injectable products and 15 dry powder injectable products, with key therapeutic categories including antibiotics (Amikacin Sulphate, Ceftriaxone), pain management (Buprenorphine), supplements (Vitamin B12, D3 & Calcium formulations), and anti-malarials (Artesunate). Products are manufactured in multiple dosage forms such as ampoules and vials, available in both single-dose and multi-dose packs.

Bio Medica Laboratories generates revenue from two primary sources: (1) the sale of manufactured goods, i.e., injectables produced in-house, and (2) the trading of raw materials and packaging materials, including base chemicals and tablets. As of FY 2025, the company reported an installed capacity of 5.70 crore ampoules and 1.65 crore vials, achieving capacity utilization of 60.21% for ampoules and 71.73% for vials. As of 31 May 2025, the company has a total of 58 permanent employees on its payroll.

Promoters of Bio Medica Laboratories – Mr. Mukesh Mehta and Mr. Pradeep Mehta

Bio Medica Laboratories IPO Details

Bio Medica Laboratories Financial Performance

Bio Medica Laboratories Offer News

Bio Medica Laboratories Valuations & Margins

Bio Medica Laboratories IPO GMP Today

Bio Medica Laboratories IPO Subscription – Live Updates

Coming soon

The market maker reservation portion of () shares and the anchor investor portion of () shares are not included in the above calculations.

Bio Medica Laboratories IPO Allotment Status

Bio Medica Laboratories IPO allotment status will be available on the Skyline Financial Services website. Click on this link to get the allotment status.

Bio Medica Laboratories IPO Dates & Listing Performance

IPO Opening Date	21 May 2026
IPO Closing Date	25 May 2026
Finalization of Basis of Allotment	26 May 2026
Initiation of refunds	27 May 2026
Transfer of shares to demat accounts	27 May 2026
IPO Listing Date	28 May 2026
Opening Price on NSE SME	Coming soon
Closing Price on NSE SME	Coming soon

Bio Medica Laboratories Offer Lead Manager

NARNOLIA FINANCIAL SERVICES LIMITED
201, 2nd Floor, Marble Arch, 236 B A.J.C Bose Road,
Kolkata, West Bengal- 700020
Phone: 033- 40501500
Email: [email protected]
Website: www.narnolia.com

Bio Medica Laboratories Offer Registrar

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED
D-153 A, 1st Floor, Okhla Industrial Area, Phase – I, New Delhi-110020
Tel: +91-11-40450193-97
E-mail: [email protected]
Website: www.skylinerta.com

BIO MEDICA LABORATORIES LIMITED
Plot No. 11B-11C, Sector-E, Sanwer Road,
Industrial Area, Industrial Estate (Indore),
Indore, Madhya Pradesh – 452015
Phone: +91- 7314102751
E-mail: [email protected]
Website: www.biomedica.co.in

IPO FAQs

What is the Bio Medica Laboratories offer size?

Bio Medica Laboratories offer size is INR NA crores.

What is the Bio Medica Laboratories offer price band?

Bio Medica Laboratories public offer price is INR NA per share.

What is the lot size of the Bio Medica Laboratories IPO?

Bio Medica Laboratories offer lot size is NA shares.

What is the Bio Medica Laboratories IPO GMP today?

Bio Medica Laboratories IPO GMP today is INR NA per share.

What is the Bio Medica Laboratories kostak rate today?

Bio Medica Laboratories kostak rate today is INR NA per application.

What is the Bio Medica Laboratories IPO Subject to Sauda rate today?

Bio Medica Laboratories Subject to Sauda rate today is INR NA per application.

Anil made his foray in stock markets quite early in career while pursuing a degree in science. This was followed by an MBA degree in finance and a rich experience ensued in the corporate sector spanning various roles in valuations, industry analysis and consulting. He found his calling in stocks market and now works full time to educate others about the amazing opportunity Indian financial markets offer.